AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERV
  4. [Form 4] Verve Therapeutics, Inc. Insider Trading Activity

[Form 4] Verve Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Lantern Pharma Inc. (LTRN) filed a preliminary proxy (Form PRE-14A) for its virtual 2025 Annual Meeting, scheduled 19 September 2025 at 11:00 a.m. ET. Holders of record on 28 July 2025 will vote on four proposals:

  • Elect six directors (current slate; five qualify as independent).
  • Reprice 314,633 underwater stock options (鈮�25 % of total outstanding options). Grants with strikes >$10 will reset to $5.04鈥�125 % of the 10-day VWAP鈥攊f holders remain employed/serving for 12 months after shareholder approval. All other terms, including vesting, remain unchanged.
  • Ratify EisnerAmper LLP as independent auditor for FY-2025 (2024 audit fees $215k; total audit-related fees $381k).
  • Authorize an adjournment if additional proxies are needed.

Share count stands at 10.78 m; the largest holder is Bios Equity entities (9.98 %). Quorum requires 33.3 % of voting power; directors are elected by plurality, other items need majority. The Board unanimously recommends FOR all proposals, citing retention and alignment benefits from the option repricing after a multi-year share-price decline (recent close $4.24). No new share issuance or financing is proposed.

Lantern Pharma Inc. (LTRN) ha depositato un proxy preliminare (Modulo PRE-14A) per la sua riunione annuale virtuale del 2025, prevista per il 19 settembre 2025 alle 11:00 ET. I detentori registrati al 28 luglio 2025 voteranno su quattro proposte:

  • Eleggere sei amministratori (lista attuale; cinque sono indipendenti).
  • Rivalutare 314.633 opzioni azionarie sottostanti (circa il 25% del totale opzioni in circolazione). Le opzioni con prezzo di esercizio superiore a $10 verranno ricalibrate a $5,04鈥�125% della VWAP a 10 giorni鈥攕e i titolari restano impiegati o in carica per 12 mesi dopo l鈥檃pprovazione degli azionisti. Tutti gli altri termini, inclusa la maturazione, rimangono invariati.
  • Ratificare EisnerAmper LLP come revisore indipendente per l鈥檈sercizio 2025 (onorari di revisione 2024 $215k; totale onorari correlati $381k).
  • Autorizzare una sospensione della riunione qualora siano necessari ulteriori proxy.

Il numero di azioni in circolazione 猫 di 10,78 milioni; il maggiore azionista 猫 Bios Equity con il 9,98%. Il quorum richiede il 33,3% del potere di voto; gli amministratori sono eletti a maggioranza relativa, mentre gli altri punti richiedono maggioranza assoluta. Il Consiglio raccomanda all鈥檜nanimit脿 di VOTARE A FAVORE di tutte le proposte, sottolineando i benefici di mantenimento e allineamento derivanti dalla rivalutazione delle opzioni dopo un calo pluriennale del prezzo delle azioni (ultimo prezzo di chiusura $4,24). Non 猫 prevista alcuna nuova emissione di azioni o finanziamento.

Lantern Pharma Inc. (LTRN) present贸 un proxy preliminar (Formulario PRE-14A) para su reuni贸n anual virtual de 2025, programada para el 19 de septiembre de 2025 a las 11:00 a.m. ET. Los titulares registrados al 28 de julio de 2025 votar谩n sobre cuatro propuestas:

  • Elegir a seis directores (lista actual; cinco califican como independientes).
  • Revalorar 314,633 opciones de acciones con precio de ejercicio superior al mercado (aproximadamente el 25% del total de opciones en circulaci贸n). Las opciones con precio superior a $10 se reajustar谩n a $5.04鈥�125% del VWAP de 10 d铆as鈥攕i los titulares permanecen empleados o en servicio durante 12 meses despu茅s de la aprobaci贸n de los accionistas. Todos los dem谩s t茅rminos, incluyendo el per铆odo de adquisici贸n, permanecer谩n sin cambios.
  • Ratificar a EisnerAmper LLP como auditor independiente para el a帽o fiscal 2025 (honorarios de auditor铆a 2024 $215k; honorarios totales relacionados con auditor铆a $381k).
  • Autorizar un aplazamiento si se necesitan proxies adicionales.

El n煤mero de acciones en circulaci贸n es de 10.78 millones; el mayor accionista es Bios Equity con un 9.98%. El qu贸rum requiere el 33.3% del poder de voto; los directores se eligen por pluralidad, los dem谩s temas requieren mayor铆a. La Junta recomienda un谩nimemente VOTAR A FAVOR de todas las propuestas, citando beneficios de retenci贸n y alineaci贸n derivados de la revalorizaci贸n de opciones tras una ca铆da prolongada del precio de las acciones (煤ltimo cierre $4.24). No se propone ninguna nueva emisi贸n de acciones ni financiamiento.

Lantern Pharma Inc. (LTRN)電� 2025雲� 9鞗� 19鞚� 鞓れ爠 11鞁�(霃欕秬鞁滉皠)鞐� 鞓堨爼霅� 2025雲� 臧�靸� 鞐半 欤检＜齑濏殞毳� 鞙勴暅 鞓堧箘 鞙勳瀯鞛� 靹滊(Form PRE-14A)毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 28鞚� 旮办 欤检＜霌れ潃 雱� 臧�歆� 鞎堦贝鞐� 雽�頃� 韴憸頃� 鞓堨爼鞛呺媹雼�:

  • 6氇呾潣 鞚挫偓 靹犾瀯 (順勳灛 氇呺嫧; 5氇呾潃 霃呺 鞚挫偓 鞛愱博).
  • 臧�瓴� 臁办爼 314,633臧滌潣 頄夓偓臧�瓴╈澊 順勳灛 欤缄皜氤措嫟 雴掛潃 鞀ろ啞鞓奠厴(鞝勳泊 氚滍枆 鞓奠厴鞚� 鞎� 25%). 頄夓偓臧�瓴╈澊 $10 鞚挫儊鞚� 鞓奠厴鞚� 欤检＜ 鞀轨澑 頉� 12臧滌洈臧� 鞛 鞁� 10鞚� VWAP鞚� 125%鞚� $5.04搿� 臁办爼霅╇媹雼�. 旮绊儉 臁瓣贝(氩犾姢韺� 韽暔)鞚� 氤�瓴诫悩歆� 鞎婌姷雼堧嫟.
  • 2025 須岅硠鞐半弰 霃呺 臧愳偓鞚胳溂搿� EisnerAmper LLP 鞀轨澑 (2024雲� 臧愳偓 靾橃垬耄� $215k; 齑� 臧愳偓 甏�霠� 靾橃垬耄� $381k).
  • 於旉皜 鞙勳瀯鞛レ澊 頃勳殧頃� 瓴届毎 須岇潣 鞐瓣赴 鞀轨澑.

氚滍枆 欤检嫕 靾橂姅 1,078毵� 欤检澊氅�, 斓滊寑 欤检＜電� Bios Equity 瓿勳棿靷 9.98%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝曥”靾橂姅 鞚橁舶甓岇潣 33.3%鞚措┌, 鞚挫偓電� 雼れ垬 霌濏憸鞝滊 靹犾稖霅橁碃 旮绊儉 鞎堦贝鞚� 瓿茧皹靾� 彀劚鞚� 頃勳殧頃╇媹雼�. 鞚挫偓須岆姅 雼る厔臧� 欤缄皜 頃橂澖 鞚错泟 鞓奠厴 臧�瓴� 臁办爼鞐� 霐半ジ 歆侅洂 鞙犾 氚� 鞚错暣甏�瓿� 鞚检箻 須臣毳� 鞚挫湢搿� 氇摖 鞎堦贝鞐� 雽�頃� 毵岇灔鞚检箻搿� 彀劚 甓岅碃毳� 頃橁碃 鞛堨姷雼堧嫟(斓滉芳 膦呹皜 $4.24). 鞁犼窚 欤检嫕 氚滍枆鞚措倶 鞛愱笀 臁半嫭 瓿勴殟鞚� 鞐嗢姷雼堧嫟.

Lantern Pharma Inc. (LTRN) a d茅pos茅 un proxy pr茅liminaire (formulaire PRE-14A) pour son assembl茅e annuelle virtuelle de 2025, pr茅vue le 19 septembre 2025 脿 11h00 ET. Les d茅tenteurs inscrits au 28 juillet 2025 voteront sur quatre propositions :

  • 脡lection de six administrateurs (liste actuelle ; cinq sont ind茅pendants).
  • 搁茅茅惫补濒耻补迟颈辞苍 de 314 633 options d鈥檃chat d鈥檃ctions sous le cours (environ 25 % du total des options en circulation). Les options avec un prix d鈥檈xercice sup茅rieur 脿 10 $ seront ajust茅es 脿 5,04 $ 鈥� soit 125 % de la VWAP sur 10 jours 鈥� si les titulaires restent employ茅s ou en fonction pendant 12 mois apr猫s l鈥檃pprobation des actionnaires. Tous les autres termes, y compris la p茅riode d鈥檃cquisition, restent inchang茅s.
  • Ratification d鈥橢isnerAmper LLP en tant qu鈥檃uditeur ind茅pendant pour l鈥檈xercice 2025 (honoraires d鈥檃udit 2024 de 215 000 $ ; honoraires totaux li茅s 脿 l鈥檃udit de 381 000 $).
  • Autorisation de la suspension de l鈥檃ssembl茅e si des procurations suppl茅mentaires sont n茅cessaires.

Le nombre d鈥檃ctions en circulation est de 10,78 millions ; le principal actionnaire est Bios Equity avec 9,98 %. Le quorum exige 33,3 % du pouvoir de vote ; les administrateurs sont 茅lus 脿 la pluralit茅, les autres points requi猫rent une majorit茅. Le conseil recommande 脿 l鈥檜nanimit茅 de VOTER POUR toutes les propositions, soulignant les avantages en termes de fid茅lisation et d鈥檃lignement r茅sultant de la r茅茅valuation des options apr猫s une baisse prolong茅e du cours de l鈥檃ction (dernier cours de cl么ture 4,24 $). Aucune nouvelle 茅mission d鈥檃ctions ou financement n鈥檈st propos茅.

Lantern Pharma Inc. (LTRN) hat eine vorl盲ufige Vollmachtserkl盲rung (Formular PRE-14A) f眉r seine virtuelle Hauptversammlung 2025 eingereicht, die f眉r den 19. September 2025 um 11:00 Uhr ET geplant ist. Die zum 28. Juli 2025 eingetragenen Aktion盲re werden 眉ber vier Vorschl盲ge abstimmen:

  • Wahl von sechs Direktoren (aktueller Kandidatenvorschlag; f眉nf gelten als unabh盲ngig).
  • Neubewertung von 314.633 unter dem aktuellen Kurs liegenden Aktienoptionen (ca. 25 % der insgesamt ausstehenden Optionen). Optionen mit Aus眉bungspreisen 眉ber $10 werden auf $5,04 zur眉ckgesetzt 鈥� 125 % des 10-Tage VWAP 鈥� sofern die Inhaber 12 Monate nach Aktion盲rszustimmung weiterhin besch盲ftigt oder im Amt sind. Alle anderen Bedingungen, einschlie脽lich der Vesting-Bedingungen, bleiben unver盲ndert.
  • Best盲tigung von EisnerAmper LLP als unabh盲ngiger Abschlusspr眉fer f眉r das Gesch盲ftsjahr 2025 (Pr眉fungsgeb眉hren 2024 $215k; insgesamt pr眉fungsbezogene Geb眉hren $381k).
  • Erm盲chtigung zur Vertagung, falls zus盲tzliche Vollmachten ben枚tigt werden.

Die Aktienanzahl betr盲gt 10,78 Mio.; der gr枚脽te Anteilseigner ist Bios Equity mit 9,98 %. Das Quorum erfordert 33,3 % der Stimmrechte; Direktoren werden nach Mehrheitswahlprinzip gew盲hlt, andere Punkte ben枚tigen eine einfache Mehrheit. Der Vorstand empfiehlt einstimmig, allen Vorschl盲gen ZUZUSTIMMEN, und verweist auf Vorteile bez眉glich Mitarbeiterbindung und Ausrichtung durch die Options-Neubewertung nach mehrj盲hrigem Kursr眉ckgang (aktueller Schlusskurs $4,24). Es sind keine neuen Aktienausgaben oder Finanzierungen geplant.

Positive
  • Majority-independent board with clear committee oversight enhances governance.
  • Option repricing strike set 19 % above market, limiting dilution while improving retention.
  • No new equity authorization; uses existing plan shares, keeping share overhang unchanged.
  • Virtual meeting increases accessibility for global shareholders.
Negative
  • Stock price has fallen significantly, leaving 25 % of options deeply underwater.
  • Repricing may be viewed as shareholder-unfriendly and could generate modest incremental accounting expense.
  • Auditor fees increased to $381k in 2024 vs. $259k in 2023.
  • Potential dilution if repriced options are exercised at $5.04 vs. prior >$10 strikes.

Insights

TL;DR: Option repricing improves staff retention but introduces modest dilution; otherwise routine proxy items鈥攏et neutral to valuation.

The repricing covers 314.6k options鈥攋ust 2.9 % of basic shares鈥攁nd sets a 19 % premium to the market, limiting immediate dilution. By requiring 12-month continued service before the lower strike applies, Lantern protects against short-term churn. No additional equity is issued, and total option overhang is unchanged. Election of incumbents and auditor ratification are procedural. Because no capital raise, dividend, or strategic shift is presented, the filing does not materially alter cash flow prospects or near-term catalysts. Investors should monitor the vote to gauge governance sentiment but, absent surprises, I view impact as neutral.

TL;DR: Board remains majority-independent; repricing signals performance misalignment yet applies shareholder-friendly safeguards鈥攏eutral governance impact.

The proxy confirms that five of six directors meet Nasdaq independence tests, with robust committee structures. Repricing underwater options can appear shareholder-unfriendly, but the Board mitigates concerns via: (1) strike set above market (125 % VWAP); (2) no acceleration of vesting; (3) 12-month retention requirement; and (4) use of existing plan shares, avoiding added dilution. Auditor fees rose YoY but remain reasonable for a micro-cap biotech. Overall, governance standards are maintained, though the need to re-align incentives highlights prior stock under-performance.

Lantern Pharma Inc. (LTRN) ha depositato un proxy preliminare (Modulo PRE-14A) per la sua riunione annuale virtuale del 2025, prevista per il 19 settembre 2025 alle 11:00 ET. I detentori registrati al 28 luglio 2025 voteranno su quattro proposte:

  • Eleggere sei amministratori (lista attuale; cinque sono indipendenti).
  • Rivalutare 314.633 opzioni azionarie sottostanti (circa il 25% del totale opzioni in circolazione). Le opzioni con prezzo di esercizio superiore a $10 verranno ricalibrate a $5,04鈥�125% della VWAP a 10 giorni鈥攕e i titolari restano impiegati o in carica per 12 mesi dopo l鈥檃pprovazione degli azionisti. Tutti gli altri termini, inclusa la maturazione, rimangono invariati.
  • Ratificare EisnerAmper LLP come revisore indipendente per l鈥檈sercizio 2025 (onorari di revisione 2024 $215k; totale onorari correlati $381k).
  • Autorizzare una sospensione della riunione qualora siano necessari ulteriori proxy.

Il numero di azioni in circolazione 猫 di 10,78 milioni; il maggiore azionista 猫 Bios Equity con il 9,98%. Il quorum richiede il 33,3% del potere di voto; gli amministratori sono eletti a maggioranza relativa, mentre gli altri punti richiedono maggioranza assoluta. Il Consiglio raccomanda all鈥檜nanimit脿 di VOTARE A FAVORE di tutte le proposte, sottolineando i benefici di mantenimento e allineamento derivanti dalla rivalutazione delle opzioni dopo un calo pluriennale del prezzo delle azioni (ultimo prezzo di chiusura $4,24). Non 猫 prevista alcuna nuova emissione di azioni o finanziamento.

Lantern Pharma Inc. (LTRN) present贸 un proxy preliminar (Formulario PRE-14A) para su reuni贸n anual virtual de 2025, programada para el 19 de septiembre de 2025 a las 11:00 a.m. ET. Los titulares registrados al 28 de julio de 2025 votar谩n sobre cuatro propuestas:

  • Elegir a seis directores (lista actual; cinco califican como independientes).
  • Revalorar 314,633 opciones de acciones con precio de ejercicio superior al mercado (aproximadamente el 25% del total de opciones en circulaci贸n). Las opciones con precio superior a $10 se reajustar谩n a $5.04鈥�125% del VWAP de 10 d铆as鈥攕i los titulares permanecen empleados o en servicio durante 12 meses despu茅s de la aprobaci贸n de los accionistas. Todos los dem谩s t茅rminos, incluyendo el per铆odo de adquisici贸n, permanecer谩n sin cambios.
  • Ratificar a EisnerAmper LLP como auditor independiente para el a帽o fiscal 2025 (honorarios de auditor铆a 2024 $215k; honorarios totales relacionados con auditor铆a $381k).
  • Autorizar un aplazamiento si se necesitan proxies adicionales.

El n煤mero de acciones en circulaci贸n es de 10.78 millones; el mayor accionista es Bios Equity con un 9.98%. El qu贸rum requiere el 33.3% del poder de voto; los directores se eligen por pluralidad, los dem谩s temas requieren mayor铆a. La Junta recomienda un谩nimemente VOTAR A FAVOR de todas las propuestas, citando beneficios de retenci贸n y alineaci贸n derivados de la revalorizaci贸n de opciones tras una ca铆da prolongada del precio de las acciones (煤ltimo cierre $4.24). No se propone ninguna nueva emisi贸n de acciones ni financiamiento.

Lantern Pharma Inc. (LTRN)電� 2025雲� 9鞗� 19鞚� 鞓れ爠 11鞁�(霃欕秬鞁滉皠)鞐� 鞓堨爼霅� 2025雲� 臧�靸� 鞐半 欤检＜齑濏殞毳� 鞙勴暅 鞓堧箘 鞙勳瀯鞛� 靹滊(Form PRE-14A)毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 28鞚� 旮办 欤检＜霌れ潃 雱� 臧�歆� 鞎堦贝鞐� 雽�頃� 韴憸頃� 鞓堨爼鞛呺媹雼�:

  • 6氇呾潣 鞚挫偓 靹犾瀯 (順勳灛 氇呺嫧; 5氇呾潃 霃呺 鞚挫偓 鞛愱博).
  • 臧�瓴� 臁办爼 314,633臧滌潣 頄夓偓臧�瓴╈澊 順勳灛 欤缄皜氤措嫟 雴掛潃 鞀ろ啞鞓奠厴(鞝勳泊 氚滍枆 鞓奠厴鞚� 鞎� 25%). 頄夓偓臧�瓴╈澊 $10 鞚挫儊鞚� 鞓奠厴鞚� 欤检＜ 鞀轨澑 頉� 12臧滌洈臧� 鞛 鞁� 10鞚� VWAP鞚� 125%鞚� $5.04搿� 臁办爼霅╇媹雼�. 旮绊儉 臁瓣贝(氩犾姢韺� 韽暔)鞚� 氤�瓴诫悩歆� 鞎婌姷雼堧嫟.
  • 2025 須岅硠鞐半弰 霃呺 臧愳偓鞚胳溂搿� EisnerAmper LLP 鞀轨澑 (2024雲� 臧愳偓 靾橃垬耄� $215k; 齑� 臧愳偓 甏�霠� 靾橃垬耄� $381k).
  • 於旉皜 鞙勳瀯鞛レ澊 頃勳殧頃� 瓴届毎 須岇潣 鞐瓣赴 鞀轨澑.

氚滍枆 欤检嫕 靾橂姅 1,078毵� 欤检澊氅�, 斓滊寑 欤检＜電� Bios Equity 瓿勳棿靷 9.98%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝曥”靾橂姅 鞚橁舶甓岇潣 33.3%鞚措┌, 鞚挫偓電� 雼れ垬 霌濏憸鞝滊 靹犾稖霅橁碃 旮绊儉 鞎堦贝鞚� 瓿茧皹靾� 彀劚鞚� 頃勳殧頃╇媹雼�. 鞚挫偓須岆姅 雼る厔臧� 欤缄皜 頃橂澖 鞚错泟 鞓奠厴 臧�瓴� 臁办爼鞐� 霐半ジ 歆侅洂 鞙犾 氚� 鞚错暣甏�瓿� 鞚检箻 須臣毳� 鞚挫湢搿� 氇摖 鞎堦贝鞐� 雽�頃� 毵岇灔鞚检箻搿� 彀劚 甓岅碃毳� 頃橁碃 鞛堨姷雼堧嫟(斓滉芳 膦呹皜 $4.24). 鞁犼窚 欤检嫕 氚滍枆鞚措倶 鞛愱笀 臁半嫭 瓿勴殟鞚� 鞐嗢姷雼堧嫟.

Lantern Pharma Inc. (LTRN) a d茅pos茅 un proxy pr茅liminaire (formulaire PRE-14A) pour son assembl茅e annuelle virtuelle de 2025, pr茅vue le 19 septembre 2025 脿 11h00 ET. Les d茅tenteurs inscrits au 28 juillet 2025 voteront sur quatre propositions :

  • 脡lection de six administrateurs (liste actuelle ; cinq sont ind茅pendants).
  • 搁茅茅惫补濒耻补迟颈辞苍 de 314 633 options d鈥檃chat d鈥檃ctions sous le cours (environ 25 % du total des options en circulation). Les options avec un prix d鈥檈xercice sup茅rieur 脿 10 $ seront ajust茅es 脿 5,04 $ 鈥� soit 125 % de la VWAP sur 10 jours 鈥� si les titulaires restent employ茅s ou en fonction pendant 12 mois apr猫s l鈥檃pprobation des actionnaires. Tous les autres termes, y compris la p茅riode d鈥檃cquisition, restent inchang茅s.
  • Ratification d鈥橢isnerAmper LLP en tant qu鈥檃uditeur ind茅pendant pour l鈥檈xercice 2025 (honoraires d鈥檃udit 2024 de 215 000 $ ; honoraires totaux li茅s 脿 l鈥檃udit de 381 000 $).
  • Autorisation de la suspension de l鈥檃ssembl茅e si des procurations suppl茅mentaires sont n茅cessaires.

Le nombre d鈥檃ctions en circulation est de 10,78 millions ; le principal actionnaire est Bios Equity avec 9,98 %. Le quorum exige 33,3 % du pouvoir de vote ; les administrateurs sont 茅lus 脿 la pluralit茅, les autres points requi猫rent une majorit茅. Le conseil recommande 脿 l鈥檜nanimit茅 de VOTER POUR toutes les propositions, soulignant les avantages en termes de fid茅lisation et d鈥檃lignement r茅sultant de la r茅茅valuation des options apr猫s une baisse prolong茅e du cours de l鈥檃ction (dernier cours de cl么ture 4,24 $). Aucune nouvelle 茅mission d鈥檃ctions ou financement n鈥檈st propos茅.

Lantern Pharma Inc. (LTRN) hat eine vorl盲ufige Vollmachtserkl盲rung (Formular PRE-14A) f眉r seine virtuelle Hauptversammlung 2025 eingereicht, die f眉r den 19. September 2025 um 11:00 Uhr ET geplant ist. Die zum 28. Juli 2025 eingetragenen Aktion盲re werden 眉ber vier Vorschl盲ge abstimmen:

  • Wahl von sechs Direktoren (aktueller Kandidatenvorschlag; f眉nf gelten als unabh盲ngig).
  • Neubewertung von 314.633 unter dem aktuellen Kurs liegenden Aktienoptionen (ca. 25 % der insgesamt ausstehenden Optionen). Optionen mit Aus眉bungspreisen 眉ber $10 werden auf $5,04 zur眉ckgesetzt 鈥� 125 % des 10-Tage VWAP 鈥� sofern die Inhaber 12 Monate nach Aktion盲rszustimmung weiterhin besch盲ftigt oder im Amt sind. Alle anderen Bedingungen, einschlie脽lich der Vesting-Bedingungen, bleiben unver盲ndert.
  • Best盲tigung von EisnerAmper LLP als unabh盲ngiger Abschlusspr眉fer f眉r das Gesch盲ftsjahr 2025 (Pr眉fungsgeb眉hren 2024 $215k; insgesamt pr眉fungsbezogene Geb眉hren $381k).
  • Erm盲chtigung zur Vertagung, falls zus盲tzliche Vollmachten ben枚tigt werden.

Die Aktienanzahl betr盲gt 10,78 Mio.; der gr枚脽te Anteilseigner ist Bios Equity mit 9,98 %. Das Quorum erfordert 33,3 % der Stimmrechte; Direktoren werden nach Mehrheitswahlprinzip gew盲hlt, andere Punkte ben枚tigen eine einfache Mehrheit. Der Vorstand empfiehlt einstimmig, allen Vorschl盲gen ZUZUSTIMMEN, und verweist auf Vorteile bez眉glich Mitarbeiterbindung und Ausrichtung durch die Options-Neubewertung nach mehrj盲hrigem Kursr眉ckgang (aktueller Schlusskurs $4,24). Es sind keine neuen Aktienausgaben oder Finanzierungen geplant.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
ADELMAN BURT A
(Last) (First) (Middle)
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
(Street)
BOSTON MA 02215
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verve Therapeutics, Inc. [ VERV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/25/2025 U(1)(2) 428,326 D (1)(2) 0 I Burt A Adelman 2002 Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $5.02 07/25/2025 D 136,139 (3) (3) Common Stock 136,139 (3) 0 D
Stock Option (right to buy) $5.73 07/25/2025 D 42,200 (3) (3) Common Stock 42,200 (3) 0 D
Stock Option (right to buy) $8.98 07/25/2025 D 43,198 (3) (3) Common Stock 43,198 (3) 0 D
Explanation of Responses:
1. In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest
2. (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
3. Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).
/s/ Andrew Ashe, as Attorney-in-Fact for Burt A Adelman 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

When is Lantern Pharma's (LTRN) 2025 Annual Meeting?

19 September 2025 at 11:00 a.m. ET, conducted virtually at www.virtualshareholdermeeting.com/LTRN2025.

What proposals will LTRN shareholders vote on?

Election of six directors, approval of one-time option repricing, ratification of EisnerAmper LLP as auditor, and authority to adjourn the meeting if needed.

How many options are subject to the repricing?

314,633 options, about 25 % of the company鈥檚 outstanding options pool.

What is the new exercise price for repriced options?

$5.04 per share鈥�125 % of the 10-day VWAP ending 24 July 2025.

Who is LTRN鈥檚 largest shareholder?

Bios Equity entities hold 1.08 m shares (9.98 %) as of 23 July 2025.

What record date determines voting eligibility?

Shareholders of record at the close of business on 28 July 2025 can vote.
Stock VERV logo
Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

#4349 Ranked by Market Cap
N/A Ranked by Dividends

VERV Latest News

Jul 25, 2025
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul 24, 2025
Lilly and Verve announce expiration of Verve tender offer
Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 2, 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 28, 2025
Verve Therapeutics to Participate in Upcoming Investor Conferences

VERV Latest SEC Filings

Jul 28, 2025
[SCHEDULE 13G/A] Verve Therapeutics, Inc. SEC Filing
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity

VERV Stock Data

994.04M
84.54M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON